Evolus Inc
Evolus Inc (EOLS) Covered Calls
Evolus Inc trades in the Drug Manufacturers - Specialty & Generic industry with an IV Rank of 44.05%, average versus the past year. EOLS's highest covered call setup is the $10.00 strike expiring Apr 16, 2027, sorted by theoretical annualized return. It's 50.83% out of the money with 151 days to expiration, a 53.85% return until expiration, and a 130.16% theoretical annualized return. Across the setups shown, annualized returns run from 49.95% to 130.16% at strikes between $7.50 and $10.00, with 151 to 151 days to expiration, as of Nov 16, 2026.
Read more
Running EOLS covered calls helps you generate income from Evolus Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best EOLS covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If EOLS stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling EOLS covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given EOLS covered call is worth writing.
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
| 2027-04-16 | 151 | 10.00 | 50.83 | 0.20 | 0.45 | 357.00 | 53.85 | 130.16 | -3.02 | +0.24 | 2,330 | 0.25 |
| 2027-04-16 | 151 | 7.50 | 13.12 | 0.50 | 1.80 | 137.00 | 20.66 | 49.95 | -7.54 | +0.53 | 9 | 1.30 |
As of Nov 16, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryDrug Manufacturers - Specialty & Generic
- SectorHealthcare
- IV Rank44.05% Moderate
- Market cap (M$)443
- 52 weeks high-28.14%
- 52 weeks low73.32%
- Analyst recommendationStrong Buy
1.33 - Target price$15.40
130.19% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-04
- P/E—
- Future P/E20.27
- EPS (ttm)-0.47
- EPS growth next 5 years—
As of Nov 17, 2026